MedTrace Logo

Doxycycline for the Prevention of Spontaneous Bacterial Peritonitis

NCT04153604 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 841

Last updated 2026-03-20

No results posted yet for this study

Summary

The utilization of doxycycline for SBP prophylaxis is a novel practice at MDMC. Therefore, an assessment of safety and efficacy is needed in order to generalize this practice. The publication of this study can potentially introduce a new alternative to guideline-directed therapies for secondary prevention of SBP. Doxycycline is non-inferior to guideline-directed therapies regarding safety and efficacy in primary and secondary prophylaxis for SBP.

Conditions

  • Cirrhosis
  • Spontaneous Bacterial Peritonitis

Interventions

DRUG

doxycycline

a tetracycline antibiotic that fights bacteria in the body.

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Jessica Rago, PharmD · The Methodist Hospital Research Institute

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-04
Primary Completion
2020-08-07
Completion
2020-08-07

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04153604 on ClinicalTrials.gov